拜瑞妥
医学
抗血栓
内科学
心脏病学
心房颤动
随机对照试验
栓塞
入射(几何)
麻醉
华法林
置信区间
左心耳阻塞
冲程(发动机)
磁共振成像
血小板聚集抑制剂
血栓形成
抗血小板药物
血栓栓塞性中风
认知
临床试验
蒙特利尔认知评估
心耳
外科
睡眠剥夺对认知功能的影响
认知功能衰退
作者
Kexin Wang,Linsheng Shi,Zhongbao Ruan,Hongwu Chen,Hailei Liu,Zidun Wang,Xiaohong Jiang,Mingfang Li,Minglong Chen,Weizhu Ju
标识
DOI:10.1093/eurheartj/ehag734
摘要
BACKGROUND AND AIMS: The optimal long-term antithrombotic strategy after left atrial appendage occlusion (LAAO) remains undetermined. The present study aimed to investigate whether half-dose rivaroxaban (10 mg daily) could better reduce silent cerebral embolic lesions (SCEs) and preserve cognitive function compared to antiplatelet therapy after successful LAAO. METHODS: In this investigator-initiated, prospective, multicenter, randomized controlled trial, patients with successful LAAO confirmed 45 days post-procedure were assigned 1:1 to half-dose rivaroxaban or antiplatelet therapy group. Diffusion-weighted magnetic resonance imaging and cognitive assessments were repeated at 90, 180 and 365 days after LAAO. The primary outcome was the patient-level incidence of any newly detected SCE during follow-up. Secondary outcomes included cognitive trajectories, SCE burden, and a composite of all-cause mortality, clinical thromboembolic events and major bleeding. RESULTS: Between December 2022 and February 2025, 164 patients were randomized. The patient-level incidence of new SCEs was significantly lower in the half-dose rivaroxaban group than in the antiplatelet therapy group (10/82 [12.2%] vs. 26/82 [31.7%]; P = 0.005). At 365 days, model-derived between-group differences favored the half-dose rivaroxaban group for both Mini-Mental State Examination (2.56; 95% confidence interval [CI] 1.11-4.01; P < 0.001) and Montreal Cognitive Assessment (2.67; 95% CI 1.07-4.26; P = 0.001) scores. The composite clinical outcome occurred in 2.4% of the half-dose rivaroxaban group vs. 11.0% of the antiplatelet therapy group (P = 0.057). CONCLUSIONS: In patients eligible for oral anticoagulation after successful LAAO, rivaroxaban 10 mg daily significantly reduced SCEs and better maintained cognitive function compared with antiplatelet therapy, with numerically fewer composite clinical events.
科研通智能强力驱动
Strongly Powered by AbleSci AI